RBC Capital raised the firm’s price target on Exelixis (EXEL) to $38 from $34 and keeps an Outperform rating on the shares. Zanzalintinib ...

The United States market has been flat over the last week but is up 24% over the past year, with earnings forecast to grow by 15% annually. In this context of robust growth expectations, identifying ...

Brookline Capital Markets initiated coverage of Exelixis (NASDAQ:EXEL) with a buy rating, highlighting the company's revenue ...

Principal Financial Group Inc. lessened its holdings in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 31.6% during the third ...

We recently compiled a list of the 10 Best Performing Biotech Stocks in 2024. In this article, we are going to take a look at ...

Fintel reports that on December 17, 2024, B of A Securities downgraded their outlook for Exelixis (NasdaqGS:EXEL) from Buy to ...

In this article, we are going to take a look at where Exelixis, Inc. (NASDAQ:EXEL) stands against the other biotech stocks. The Booming Biotechnology Sector The biotechnology sector is expanding ...

According to Benzinga Pro, Exelixis's peer group average for short interest as a percentage of float is 4.93%, which means ...

In the expanding oncology market, Exelixis (EXEL) is gaining attention with its strong pipeline and impressive stock ...

Analysts have set 12-month price targets for Exelixis, revealing an average target of $32.53, a high estimate of $39.00, and ...

Equities research analysts at Zacks Research boosted their Q4 2024 earnings per share (EPS) estimates for Exelixis in a ...

As previously reported, BofA downgraded Exelixis (EXEL) to Neutral from Buy with a price target of $39, up from $35. The stock price has gained ...